BOSTON – During a panel talk at Biopharm America on how collaborations between pharmaceutical firms and venture capital (VC) are changing the industry, New York-based Pfizer Inc.'s Anthony Berry said that "oftentimes we might look to join [as a limited partner (LP)] in a fund that might have a specific niche or opportunity" representing "a complement to what we're doing, not necessarily in direct competition with something we might be doing on our own." Such moves "certainly help us get a firsthand look at those companies from a different perspective than just being shopped around from the outside."